RecruitingPHASE1, PHASE2NCT06530849

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Intervention
GC012F Injection(drug)
Enrollment
118 enrolled
Eligibility
18-70 years · All sexes
Timeline
2024 – 2027

Study locations (2)

Collaborators

AstraZeneca · Suzhou Gracell Biotechnologies Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06530849 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials